The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-21. Anything still debated is marked as such rather than presented as settled.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
The government also introduced facilitation measures for international media, including visa-on-arrival arrangements for foreign journalists covering the talks and shuttle transport services between designated media area, Jinnah Convention Centre, and Serena Hotel.
The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is a global professional association that promotes the fields of clinical chemistry and laboratory medicine. It was established in Paris in 1952 as the International Association of Clinical Biochemists to organize the various national societies of these fields and is based in Milan, Italy. The IFCC's aims are to set global standards, support and educate its members, and provide conferences and other gatherings for sharing knowledge among the global laboratory medicine community. IFCC members fall into three groups: national societies of clinical chemistry and laboratory medicine, corporations, and affiliate international or national societies involved in laboratory medicine. As of 2023, these members represented more than 45,000 individual clinical chemists, laboratory scientists, and laboratory physicians.
=== Pharmacokinetics === Ketamine is effectively metabolized by the superfamily of cytochrome P450 enzymes, particularly CYP2B6 and CYP3A. Though these enzymes are predominantly found in the liver, they are present in many other organs and tissue groups throughout the body, localized to the endoplasmic reticulum of such cells. Peak concentration of norketamine occurs roughly 17 minutes after initially administering ketamine. The subsequent metabolism of norketamine to hydroxynorketamine and dehydronorketamine from ketamine occurs 2–3 hours after ketamine infusion, and occurs at a roughly 30:70 formation ratio. HNK is formed via the hydroxylation of the cyclohexone ring; these are then conjugated with glucoronic acid to form DHNK. As with their precursors ketamine and norketamine, HNK and DHNK are of great interest to pharmacologists for their putative anti-depressant and analgesic properties.
== Side effects == An overdose of bisoprolol can lead to fatigue, hypotension, hypoglycemia, bronchospasms, and bradycardia. Bronchospasms and hypoglycemia occur because at high doses, the drug can be an antagonist for β2 adrenergic receptors located in the lungs and liver. Bronchospasm occurs due to the blockage of β2 receptors in the lungs. Hypoglycemia occurs due to decreased stimulation of glycogenolysis and gluconeogenesis in the liver via β2 receptors. There have been no reported cases of clinically evident drug-induced liver injury associated with bisoprolol.
A study of proteins in cerebrospinal fluid indicates there are five subtypes of Alzheimer's disease, suggesting it to be likely that subtype-specific treatments are required. A study finds seaweed farming could be set up as a resilient food solution within roughly a year in abrupt sunlight reduction scenarios such as after a nuclear war or a large volcano eruption. 10 January Chemists report studies finding that long-chain fatty acids were produced in ancient hydrothermal vents. Such fatty acids may have contributed to the formation of the first cell membranes that are fundamental to protocells and the origin of life. Scientists report the extinction of Gigantopithecus blacki, the largest primate to ever inhabit the Earth, that lived between 2 million and 350,000 years ago, was largely due to the inability of the ape to adapt to a diet better suited to a significantly changed environment. 11 January Biologists report the discovery of the oldest known skin, fossilized about 289 million years ago, and possibly the skin from an ancient reptile. Scientists report the discovery of Tyrannosaurus mcraeensis, an older species of Tyrannosaurus that lived 5-7 million years before Tyrannosaurus rex, and which may be fundamentally important to the evolution of the species. A study of the Caatinga region in Brazil finds that its semi-arid biome could lose over 90% of mammal species by 2060, even in a best-case scenario of climate change.
Sources: en.wikipedia.org
Grace is an American chemical business based in Columbia, Maryland. It produces specialty chemicals and specialty materials in two divisions: Performance Catalyst Solutions and Material Technologies. Performance Catalyst Solutions markets refining catalysts, polyethylene and polypropylene catalysts and related products and technologies used in petrochemical, refining, and other chemical manufacturing applications. Material Technologies makes specialty materials, including silica-based and silica-alumina-based materials, which are used in commercial products such as coatings and paints, consumer products such as toothpaste, and in chemical process applications, as well as Fine Chemical Manufacturing Services. For much of its early history, Grace's main business was in South America, in maritime shipping, railroads, agriculture, and silver mining, with 30,000 employees in Peru. In the 1950s, Grace began to diversify and grew into a Fortune 100 worldwide conglomerate. After emerging from a prolonged bankruptcy period of 12 years in 2014, the company spun off its other major operating divisions. In 2015, Grace separated into two independent public companies. Its Catalysts and Material Technologies business segments remained in Grace, and what would later become GCP Applied Technologies Inc. held its Grace Construction Products (GCP) and Darex Packaging Technologies businesses. In September 2021, Standard Industries acquired Grace (the Catalysts and Material Technologies business segments).
Research published by the RAC indicates that the target set by the UK government for installing rapid or ultra-rapid chargers near motorways was missed during 2023. Provisional data released by the Met Office indicates 2023 was the second warmest year on record in the UK behind 2022, with Wales and Northern Ireland experiencing their warmest year on record during 2023. 16-year-old Luke Littler beats Rob Cross to reach the World Darts Championship final, making him the youngest person to reach the final; overtaking Kirk Shepherd who was 21 years and 88 days old when he reached the 2008 final. 3 January Luke Littler becomes the youngest finalist of the PDC World Darts Championship as he faces Luke Humphries in the 2024 final at the age of 16 years and 348 days. Humphries wins the final. Halifax, the UK's largest moneylender, cuts its mortgage rates by almost 1%, with other banks and lenders following. 4 January Prime Minister Rishi Sunak says his "working assumption" is that the general election will take place in the second half of this year. Sainsbury's announces that they will offer pay rises from March as supermarkets continue their battle to retain workers. The increase means that all their workers will be paid the voluntary Real Living Wage, which is higher than the compulsory National Living Wage. A man is arrested after firing shots at a cinema, newsagent, and a house in Croxteth, Liverpool.
== Politics == Christian Heritage Party (disambiguation) Christian Historical Party (1903–1908), a Dutch conservative party Republican People's Party (Cumhuriyet Halk Partisi), a Turkish centre-left party
== Mechanism of action == P11-4 is an α-peptide that self-assembles into β-sheet amyloids with a hydrogel appearance at low pH. It builds a 3-D bio-matrix with binding sites for calcium ions serving as nucleation point for hydroxyapatite (tooth mineral) formation. The high affinity to tooth mineral is based on matching distances of Ca-ion binding sites on P11-4 and Ca spacing in the crystal lattice of hydroxyapatite. The matrix formation is pH controlled and thus allows control matrix activity and place of formation.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.